Frank Mottola - 26 Feb 2025 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
SVP, Quality, GMP, Ops, IT
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol
SUPN
Transactions as of
26 Feb 2025
Net transactions value
-$113,900
Form type
4
Filing time
26 Feb 2025, 17:56:45 UTC
Previous filing
24 Feb 2025
Next filing
05 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Options Exercise $0 +2,010 +16% $0.000000 14,909 26 Feb 2025 Direct
transaction SUPN Common Stock Tax liability $38,532 -976 -6.5% $39.48 13,933 26 Feb 2025 Direct F1
transaction SUPN Common Stock Options Exercise $0 +3,750 +27% $0.000000 17,683 26 Feb 2025 Direct
transaction SUPN Common Stock Tax liability $75,367 -1,909 -11% $39.48 15,774 26 Feb 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Performance Share Units Options Exercise $0 -2,010 -100% $0.000000 0 26 Feb 2025 Common Stock 2,010 $0.000000 Direct F2
transaction SUPN Performance Share Units Options Exercise $0 -3,750 -100% $0.000000 0 26 Feb 2025 Common Stock 3,750 $0.000000 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
F2 On February 22, 2022, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022.
F3 On February 23, 2023, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023.